| Trastuzumab deruxtecan in previously treated HER2-positive breast cancer S Modi, C Saura, T Yamashita, YH Park, SB Kim, K Tamura, F Andre, ... New England Journal of Medicine 382 (7), 610-621, 2020 | 1526 | 2020 |
| Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer S Modi, W Jacot, T Yamashita, J Sohn, M Vidal, E Tokunaga, J Tsurutani, ... New England Journal of Medicine 387 (1), 9-20, 2022 | 1128 | 2022 |
| The genomic landscape of endocrine-resistant advanced breast cancers P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ... Cancer cell 34 (3), 427-438. e6, 2018 | 797 | 2018 |
| Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer IE Krop, M Beeram, S Modi, SF Jones, SN Holden, W Yu, S Girish, ... J Clin Oncol 28 (16), 2698-2704, 2010 | 676 | 2010 |
| Unlocking the potential of antibody–drug conjugates for cancer therapy JZ Drago, S Modi, S Chandarlapaty Nature Reviews Clinical Oncology 18 (6), 327-344, 2021 | 604 | 2021 |
| Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low–expressing advanced breast cancer: results from a phase Ib study S Modi, H Park, RK Murthy, H Iwata, K Tamura, J Tsurutani, ... Journal of Clinical Oncology 38 (17), 1887, 2020 | 586 | 2020 |
| Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers K Jhaveri, T Taldone, S Modi, G Chiosis Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1823 (3), 742-755, 2012 | 509 | 2012 |
| HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing … S Modi, A Stopeck, H Linden, D Solit, S Chandarlapaty, N Rosen, ... Clinical Cancer Research 17 (15), 5132-5139, 2011 | 492 | 2011 |
| Systemic therapy for patients with advanced human epidermal growth factor receptor 2–positive breast cancer: American Society of Clinical Oncology clinical practice guideline SH Giordano, S Temin, JJ Kirshner, S Chandarlapaty, JR Crews, ... Journal of clinical oncology 32 (19), 2078, 2014 | 456 | 2014 |
| Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2–overexpressing breast cancer: a phase I dose-escalation study S Modi, AT Stopeck, MS Gordon, D Mendelson, DB Solit, R Bagatell, ... Journal of clinical oncology 25 (34), 5410-5417, 2007 | 412 | 2007 |
| A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer who were previously treated with … IE Krop, P LoRusso, KD Miller, S Modi, D Yardley, G Rodriguez, ... Journal of clinical oncology 30 (26), 3234-3241, 2012 | 402 | 2012 |
| Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study K Tamura, J Tsurutani, S Takahashi, H Iwata, IE Krop, C Redfern, ... The Lancet Oncology 20 (6), 816-826, 2019 | 330 | 2019 |
| A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti–PD-1 agent pembrolizumab PS Adusumilli, MG Zauderer, I Rivière, SB Solomon, VW Rusch, ... Cancer discovery 11 (11), 2748-2763, 2021 | 265 | 2021 |
| Incidence of chemotherapy‐induced, long‐term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane MN Fornier, S Modi, KS Panageas, L Norton, C Hudis Cancer 104 (8), 1575-1579, 2005 | 255 | 2005 |
| The epichaperome is an integrated chaperome network that facilitates tumour survival A Rodina, T Wang, P Yan, EDG Gomes, MPS Dunphy, N Pillarsetty, ... Nature 538 (7625), 397-401, 2016 | 247 | 2016 |
| Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer S Chandarlapaty, RA Sakr, D Giri, S Patil, A Heguy, M Morrow, S Modi, ... Clinical Cancer Research 18 (24), 6784-6791, 2012 | 219 | 2012 |
| Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO clinical practice guideline update SH Giordano, S Temin, S Chandarlapaty, JR Crews, FJ Esteva, ... J Clin Oncol 36 (26), 2736-2740, 2018 | 218 | 2018 |
| Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2–positive breast cancer and brain metastases: American Society of … N Ramakrishna, S Temin, S Chandarlapaty, JR Crews, NE Davidson, ... Journal of clinical oncology 32 (19), 2100, 2014 | 211 | 2014 |
| Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study K Shitara, H Iwata, S Takahashi, K Tamura, H Park, S Modi, J Tsurutani, ... The Lancet Oncology 20 (6), 827-836, 2019 | 192 | 2019 |
| Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions K Jhaveri, SO Ochiana, MPS Dunphy, JF Gerecitano, AD Corben, RI Peter, ... Expert opinion on investigational drugs 23 (5), 611-628, 2014 | 185 | 2014 |
